Trial Profile

A single-center, open-label, single-arm, 13-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in Alzheimer's Disease (AD)- REIMAGINE-AD

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vafidemstat (Primary)
Indications Alzheimer's disease
Focus Therapeutic Use
Acronyms REIMAGINE-AD
Sponsors Oryzon

Most Recent Events

06 Jul 2023 Status changed from active, no longer recruiting to completed.
09 Mar 2021 Results published in the Oryzon Media Release.
09 Mar 2021 According to an Oryzon media release, new data from this study will be presented today at the 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD-2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com